Table 5.

Response assessment using individual MR biomarkers (tCho concentration, ADC and volume) and in combination using pathological and clinical response as gold standards for patients monitored at Tp3.

	Pathological response		Clinical response
tCho
	R	NR	R	NR
R	16	6	20	4
NR	8	11	6	11
Sens: 66.7%; Spec: 64.7%; Acc: 65.9%; PPV: 72.7%; NPV: 57.9 %			Sens: 76.9%; Spec: 73.3%; Acc: 75.6%; PPV: 83.3%; NPV:64.7%
ADC
	R	NR	R	NR
R	10	4	14	0
NR	14	13	12	15
Sens: 41.7%; Spec: 76.5%; Acc: 56.1%; PPV: 71.4%; NPV:42.2%			Sens: 53.9%; Spec: 100%; Acc: 70.7%; PPV: 100%; NPV: 55.6%
Volume
	R	NR	R	NR
R	20	8	25	3
NR	4	9	1	12
Sens: 83.3%; Spec: 52.9%; Acc: 70.7%; PPV: 71.4%; NPV:69.2%			Sens: 96.2%; Spec: 80.0%; Acc: 90.2%; PPV: 89.3%; NPV: 92.3%
Multiparametric-tCho-ADC-volume
	R	NR	R	NR
R	16	7	22	0
NR	8	10	4	15
Sens: 66.7%; Spec: 58.8%; Acc: 63.4%; PPV: 70.0%; NPV: 55.6%			Sens: 84.6%; Spec: 100%; Acc: 90.2%;PPV: 100%; NPV: 79%

Sens, sensitivity; Spec, specificity; Acc, Accuracy; PPV, positive predictive value; NPV, negative predictive value; R, Response; NR, No-response.